Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)

BACKGROUND: The continuum of anti-HER2 agents is a standard treatment of HER2 + metastatic breast cancer (MBC). This study evaluated the efficacy of lapatinib plus vinorelbine in patients progressed on both trastuzumab and lapatinib treatments. METHODS: A total of 149 patients were randomly assigned...

Descripción completa

Detalles Bibliográficos
Autores principales: Sim, Sung Hoon, Park, In Hae, Jung, Kyung Hae, Kim, Sung-Bae, Ahn, Jin-Hee, Lee, Kyung-Hun, Im, Seock-Ah, Im, Young-Hyuck, Park, Yeon Hee, Sohn, Joohyuk, Kim, Yu Jung, Lee, Suee, Kim, Hee-Jun, Chae, Yee Soo, Park, Kyong Hwa, Nam, Byung-Ho, Lee, Keun Seok, Ro, Jungsil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964682/
https://www.ncbi.nlm.nih.gov/pubmed/31690831
http://dx.doi.org/10.1038/s41416-019-0618-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964682/
https://www.ncbi.nlm.nih.gov/pubmed/31690831
http://dx.doi.org/10.1038/s41416-019-0618-z

Ejemplares similares